MDXHEALTH SA MDXH 深 滬
已收盤 10-31 16:00:00 美东时间
4.92
+0.040
+0.82%
華盛通- 最 高4.98
- 今 開4.88
- 成交量 13.14万股
- 最 低 4.72
- 昨 收 4.88
- 總市值 2.44亿
- 52周最高 5.33
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.35
- 委 比 24.53%
- 總股本 4949.73万
- 歷史最高 131.70
- 量 比 0.19
- 振 幅 5.33%
- 歷史最低 1.35
- 每 手 1
- 風險率 0.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne
<p>MDxHealth完成了对Exosome Diagnostics的收购，包括ExoDx Prostate测试及实验室。总金额为1500万美元，其中500万美元已付，剩余1000万美元将在4年内分期支付。XMS Capital Partners和K&L Gates分别为财务和法律顾问。此次收购旨在整合精准诊断技术，提升公司的产品组合。</p>
09-15 21:29
Bio-Techne Stock Upgraded As Analyst Flags Attractive Entry Point
RBC Capital upgraded Bio-Techne, citing M&A confidence, margin gains, and growth potential after a sharp stock drop and alignment with sector valuations.
09-04 02:45
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
Insights Ahead: MDxHealth's Quarterly Earnings
MDxHealth (NASDAQ:MDXH) is gearing up to announce its quarterly earnings on Thu...
08-14 03:03
Bio-Techne Corporation Announces Agreement Where Mdxhealth SA Will Acquire Its Exosome Diagnostics Inc. Business, Including The ExoDx Prostate Test, CLIA-Certified Clinical Laboratory And Related Assets. Under Agreement Bio-Techne Will Receive $5M In MDXH Stock
Bio-Techne Corporation (NASDAQ:TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory
08-06 04:59
Bio-Techne Announces Exosome Diagnostics Divestiture
MINNEAPOLIS, Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including ...
08-06 04:30
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
MDxHealth在2025年第二季度实现了20%的收入增长，达到2660万美元，并通过收购Bio-Techne的ExoDx业务，进一步扩展其前列腺癌液基诊断能力，预计将在2025年第四季度提升调整后EBITDA。
08-05 20:01
Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change
MDxHealth announced the appointment of Michael Holder as Chairman of the Audit Committee, succeeding Regine Slagmulder. Holder brings over 30 years of experience in biotech, medtech, and pharma. Ron Kalfus, the former CFO, is resigning, with Scott McMahan暂时代理该职位。The company thanked Kalfus for his six years of service.
07-03 17:00
Earnings Scheduled For May 14, 2025
Companies Reporting Before The Bell • Cellebrite DI (NASDAQ:CLBT) is expected t...
05-14 16:32
MDxHealth Schedules Key Shareholders’ Meetings for May 2025
The latest update is out from MDxHealth ( ($MDXH) ). MDxHealth SA has announced...
05-03 04:28
